Maya Said Al-Maawali
Comparative effectiveness and safety of rivaroxaban and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in an Omani tertiary care hospital.
Al-Maawali, Maya Said; Al-Naamani, Hamed Hilal; Neshat Mokadem, Leila; Al-Maawali, Ghalib; Salman, Bushra; Al-Zakwani, Ibrahim
Authors
Hamed Hilal Al-Naamani
Mrs Leila Neshat Mokadem l.neshat-mokadem@rgu.ac.uk
Senior Lecturer
Ghalib Al-Maawali
Bushra Salman
Ibrahim Al-Zakwani
Abstract
The aim of the study was to compare the effectiveness and safety of rivaroxaban and warfarin as well as to determine the appropriateness of dosing and prescribing of rivaroxaban in Omani patients with non-valvular atrial fibrillation (NVAF). This retrospective cohort study was conducted using the Royal Hospital data registry. The study included all adults newly diagnosed with NVAF and treated with rivaroxaban or warfarin. The outcomes measured include ischaemic stroke, gastrointestinal bleeding (GIB), non-gastrointestinal bleeding (NGIB), as well as appropriateness of dosing and prescribing of rivaroxaban. The analysis included 96 rivaroxaban users and 183 warfarin users; 51% of the cohort included males. There were no significant differences observed in the risk of ischaemic stroke between the two groups (hazard ratio (HR), 1.1; 95% confidence interval (CI): 0.4-3.4; p=0.8). However, those on rivaroxaban exhibited a significantly higher rate of GIB compared to those on warfarin (HR, 5.9; 95% CI: 2.9-11.7; p=0.001). There were no differences observed with regards to NGIB between the two groups (HR, 0.9; 95% CI: 0.4-1.9; p=0.8). Dosing and prescribing of rivaroxaban were found to be appropriate in 89% of the patients, with only 6% being prescribed an inappropriately lower dose. The study demonstrated no significant differences in the risk of ischaemic stroke or NGIB between rivaroxaban and warfarin groups in newly diagnosed NVAF patients. However, rivaroxaban users were found to have a significantly higher risk of GIB. Rivaroxaban was appropriately prescribed to the majority of the patients, and only a small proportion of the group received an inappropriately lower dose of rivaroxaban.
Citation
AL-MAAWALI, M.S., AL-NAAMANI, H.H., NESHAT MOKADEM, L., AL-MAAWALI, G., SALMAN, B. and AL-ZAKWANI, I. 2022. Comparative effectiveness and safety of rivaroxaban and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in an Omani tertiary care hospital. Open cardiovascular medicine journal [online], 16, article e187419242202281. Available from: https://doi.org/10.2174/18741924-v16-e2202281
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 13, 2022 |
Online Publication Date | Jun 20, 2022 |
Publication Date | Dec 31, 2022 |
Deposit Date | Oct 13, 2022 |
Publicly Available Date | Oct 13, 2022 |
Journal | Open cardiovascular medicine journal |
Electronic ISSN | 1874-1924 |
Publisher | Bentham Open |
Peer Reviewed | Peer Reviewed |
Volume | 16 |
Article Number | e187419242202281 |
DOI | https://doi.org/10.2174/18741924-v16-e2202281 |
Keywords | Non-valvular atrial fibrillation; Rivaroxaban; Warfarin; Ischaemic stroke; Gastrointestinal bleeding; Non-gastrointestinal bleeding |
Public URL | https://rgu-repository.worktribe.com/output/1778013 |
Files
AL-MAAWALI 2022 Comparative effectiveness (VOR)
(559 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
Copyright Statement
© 2022 Al-Maawali et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
You might also like
Equity, diversit[y], inclusion: exciting first steps of a winding journey.
(2022)
Presentation / Conference Contribution
Global citizenship framework.
(2022)
Presentation / Conference Contribution
Inclusive curricula design and delivery: demonstrating impact at course level.
(2022)
Presentation / Conference Contribution
Co-designing the learning experience: seeking student pharmacists' opinions of and recommendations for patient and carer involvement in active teaching in the undergraduate curriculum.
(2023)
Presentation / Conference Contribution
Downloadable Citations
About OpenAIR@RGU
Administrator e-mail: publications@rgu.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search